1. Home
  2. SLN vs PKOH Comparison

SLN vs PKOH Comparison

Compare SLN & PKOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • PKOH
  • Stock Information
  • Founded
  • SLN 1994
  • PKOH 1907
  • Country
  • SLN United Kingdom
  • PKOH United States
  • Employees
  • SLN N/A
  • PKOH N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • PKOH Industrial Specialties
  • Sector
  • SLN Health Care
  • PKOH Industrials
  • Exchange
  • SLN Nasdaq
  • PKOH Nasdaq
  • Market Cap
  • SLN 223.4M
  • PKOH 355.7M
  • IPO Year
  • SLN N/A
  • PKOH N/A
  • Fundamental
  • Price
  • SLN $4.23
  • PKOH $22.27
  • Analyst Decision
  • SLN Buy
  • PKOH
  • Analyst Count
  • SLN 5
  • PKOH 0
  • Target Price
  • SLN $40.80
  • PKOH N/A
  • AVG Volume (30 Days)
  • SLN 282.3K
  • PKOH 17.8K
  • Earning Date
  • SLN 02-27-2025
  • PKOH 03-05-2025
  • Dividend Yield
  • SLN N/A
  • PKOH 2.18%
  • EPS Growth
  • SLN N/A
  • PKOH 284.21
  • EPS
  • SLN N/A
  • PKOH 2.40
  • Revenue
  • SLN $43,258,000.00
  • PKOH $1,656,200,000.00
  • Revenue This Year
  • SLN N/A
  • PKOH $2.85
  • Revenue Next Year
  • SLN N/A
  • PKOH $4.63
  • P/E Ratio
  • SLN N/A
  • PKOH $7.18
  • Revenue Growth
  • SLN 36.71
  • PKOH N/A
  • 52 Week Low
  • SLN $4.06
  • PKOH $22.02
  • 52 Week High
  • SLN $27.72
  • PKOH $34.50
  • Technical
  • Relative Strength Index (RSI)
  • SLN 41.17
  • PKOH 35.93
  • Support Level
  • SLN $4.10
  • PKOH $22.43
  • Resistance Level
  • SLN $5.23
  • PKOH $24.21
  • Average True Range (ATR)
  • SLN 0.40
  • PKOH 0.91
  • MACD
  • SLN 0.06
  • PKOH -0.10
  • Stochastic Oscillator
  • SLN 33.90
  • PKOH 7.37

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives most of the revenue from the Supply Technologies segment which provides the customer with total supply management services such as engineering and design support, supplier selection, quality assurance, barcoding, product packaging and tracking, just-in-time and point-of-use delivery and electronic billing services for a range of production components.

Share on Social Networks: